These studies intriguingly identify particular subsets of pancreatic cancer, those with Kras mutations and PTEN deficiencies, that may be more responsive to treatment with mTOR inhibitors and/or inhibitors of MAPK/ERK, PI3K, and NF-κ B (mediators of converging signaling pathways). This evidence concerns the gene KRAS and familial pancreatic carcinoma.